First Time Loading...

JW (Cayman) Therapeutics Co Ltd
HKEX:2126

Watchlist Manager
JW (Cayman) Therapeutics Co Ltd Logo
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Watchlist
Price: 1.7 HKD -2.86% Market Closed
Updated: Apr 27, 2024

JW (Cayman) Therapeutics Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

JW (Cayman) Therapeutics Co Ltd
Net Income (Common) Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Net Income (Common)
-¥768m
CAGR 3-Years
23%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Income (Common)
-¥13.6B
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Net Income (Common)
-¥1B
CAGR 3-Years
-1%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Income (Common)
¥1.2B
CAGR 3-Years
23%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Income (Common)
¥8.5B
CAGR 3-Years
40%
CAGR 5-Years
47%
CAGR 10-Years
45%
Imeik Technology Development Co Ltd
SZSE:300896
Net Income (Common)
¥1.3B
CAGR 3-Years
61%
CAGR 5-Years
73%
CAGR 10-Years
N/A

See Also

What is JW (Cayman) Therapeutics Co Ltd's Net Income (Common)?
Net Income (Common)
-768m CNY

Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Net Income (Common) amounts to -768m CNY.

What is JW (Cayman) Therapeutics Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-23%

Over the last year, the Net Income (Common) growth was 9%. The average annual Net Income (Common) growth rates for JW (Cayman) Therapeutics Co Ltd have been 23% over the past three years , -23% over the past five years .